PT - JOURNAL ARTICLE AU - Tavera-Rodríguez, Pilar AU - Barbosa-Ramírez, Juliana AU - Bermúdez-Forero, Andrea AU - Prada-Cardozo, Diego AU - Reales-González, Jhonnatan AU - Peláez-Carvajal, Dioselina AU - Malo-Sanchez, Diana AU - Meneses-Gil, Maria-Ximena AU - Mercado-Reyes, Marcela TI - Severe acute respiratory syndrome coronavirus 2 breakthrough infections in healthcare workers vaccinees with BNT162b2 (Pfizer-BioNtech) in Bogotá, Colombia AID - 10.1101/2022.05.31.22274501 DP - 2022 Jan 01 TA - medRxiv PG - 2022.05.31.22274501 4099 - http://medrxiv.org/content/early/2022/06/01/2022.05.31.22274501.short 4100 - http://medrxiv.org/content/early/2022/06/01/2022.05.31.22274501.full AB - The healthcare workers are considered as a high-risk group for infection with SARS-CoV-2, so they were included in the first stage of the National Plan for Vaccination against COVID-19 in Colombia.An ongoing prospective cohort study to evaluate immune response to vaccination included 490 workers from health institutions in Bogotá, Colombia, vaccinated between March and June 2021 with BNT162b2 (Pfizer-BioNtech). Multiple samples were collected during a follow-up period of 6 months after immunization. We report cases of asymptomatic and symptomatic SARS-CoV-2 infections detected in this cohort. For each participant demographic data, vaccination dates, results for SARS-CoV-2 RT-PCR, and detection of antibody (IgG) tests during the follow-up period were collected.SARS-CoV-2 infection was detected in 38 (7.7 %) volunteers. Of these, 81.6% had a positive RT-PCR for SARS-CoV-2, and 18.4% were confirmed by detection of IgG anti-SARS-CoV-2 nucleoprotein; 76.3% of infections occurred after 7 days of second dose. A total of 57.9% of the cases were asymptomatic. No hospitalizations or deaths were registered. When infection occurred, 81.6% of infected participants had presence of IgG anti-S antibodies. In 12 samples in which genomic characterization was achieved, 83.4% corresponded to the variant Mu, 8.3% Gamma, and 8.3% Delta.All findings agree with other reports in different studies that show the benefit of COVID-19 vaccines, protecting specially against severe disease but not against infection or re-infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by Instituto Nacional de Salud-Colombia. No external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Our "Comite de Etica y Metodologias de Investigacion" (Commitee for ethics and metodology of research) of the Instituto Nacional de Salud - Colombia gave ethical approval for this work, project code: CEMIN 04-2021I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors